For decades, the general health and science information landscape has provided the public with foundational knowledge about bone health, medication safety, and the importance of informed medical decision-making. This legacy of accessible, neutral education has empowered individuals to understand the benefits and risks associated with common treatments, including those for osteoporosis. Within this broad context, the bisphosphonate class of drugs—such as Fosamax—has been widely discussed in terms of their role in maintaining bone density. As public awareness matured, attention gradually shifted from general therapeutic efficacy to more specific, long-term safety considerations, particularly regarding rare but serious adverse events. This evolution naturally leads to a more focused occupational and environmental exposure concern. In mass production settings—such as pharmaceutical manufacturing facilities, research laboratories, or clinical environments where these compounds are handled in bulk—workers may face unique, repeated exposure risks that differ from those of the typical patient. The transition from a general health information framework to an occupational health perspective requires acknowledging that chronic, low-level contact with active pharmaceutical ingredients can present distinct challenges. For example, individuals working in production lines or packaging areas may encounter dust, aerosols, or surface residues over extended periods. This occupational exposure context raises important questions about monitoring, protective measures, and potential long-term health implications, including the risk of osteonecrosis of the jaw, without delving into specific mechanistic claims.
Building on the occupational exposure framework, it is essential to examine the specific risks associated with Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use is associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). ONJ involves the death of jawbone tissue, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
The clinical presentation of ONJ typically includes exposed necrotic bone in the maxillofacial region that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, often following dental procedures such as tooth extraction or implant placement. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
The mechanistic pathways linking Fosamax to ONJ involve the drug's inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate suppress bone turnover, which can impair the jawbone's ability to repair microdamage and respond to local infections or trauma. This suppression, combined with reduced blood supply and local inflammation, may lead to necrosis. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
The incidence of ONJ is rare. In a study examining bisphosphonate use, the incidence of ONJ was reported as rare, while atypical femoral fracture was uncommon (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). The optimal duration of Fosamax use has not been determined; for patients at low risk for fracture, consideration of drug discontinuation after three to five years is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Regarding the adequacy of warnings, the Fosamax label includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that the time to onset of symptoms can vary widely, and that a subset of patients may experience recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide some guidance but may not fully address the risk for all patients, particularly those with multiple risk factors. For affected patients in Ohio, attorney-related considerations involve the statute of limitations for filing a lawsuit related to Fosamax and ONJ. The statute of limitations is a legal time limit within which a lawsuit must be filed. In Ohio, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because ONJ can develop months to years after starting Fosamax, and the harm may not be immediately apparent. Patients who have experienced ONJ after using Fosamax should consult with an attorney to determine whether their claim falls within the applicable statute of limitations. The timeline between exposure to Fosamax and documented harm is variable, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability can complicate the determination of when the statute of limitations begins to run.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for personal injury claims, including those related to pharmaceutical products like Fosamax, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. Because ONJ can develop months to years after starting Fosamax, it is important to consult an attorney promptly to determine if your claim falls within this timeframe.
Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.